Breathing treatment apparatus

Information

  • Patent Grant
  • 7909033
  • Patent Number
    7,909,033
  • Date Filed
    Thursday, May 3, 2007
    17 years ago
  • Date Issued
    Tuesday, March 22, 2011
    13 years ago
Abstract
The present invention relates to a method and apparatus for treating a variety of breathing disorders experienced by patients. The invention is particularly suited to the treatment of atelectasis, the partial or total collapse of the lung, although those skilled in the art will appreciate that it has applications in treating other disorders as well. Treating patients with breathing disorders traditionally has required the use of multiple types of apparatus in order to provide the multiple types of treatment used. The present invention provides for a treatment apparatus that is enabled to provide multiple types of treatment, depending on the needs of the patient.
Description
FIELD OF THE INVENTION

The invention relates to a therapeutic breathing device that delivers multiple therapies in order to facilitate the prevention and treatment of certain pulmonary diseases.


BACKGROUND OF THE INVENTION

Atelectasis is the partial or total collapse of the lung. Although this condition may occur as a result of pressure being exerted from outside the lungs by such maladies as a tumor or fluid buildup in the pleural space, it is most often caused by obstruction within the airways. When blockage develops the air in the small air sacs, or alveoli, on the distal side of the obstruction is absorbed into the bloodstream and the air sacs become diminished in size or collapse. These alveoli then often fill with blood cells, mucus, or serum, making them highly susceptible to infection. Atelectasis may happen suddenly or gradually manifest over a long period of time. In either case the disorder may lead to shortness of breath, decreased oxygen levels, increased heart rate, and infection, which in turn can result in outcomes ranging from simple discomfort to death.


Traditionally, prevention and treatment of atelectasis have included a wide variety of devices that facilitate treatment in three main areas: 1) medicated aerosol delivery, 2) lung expansion therapy, and 3) secretion clearance therapy. The variety of devices used in these therapies presents a number of problems. First, for any given patient it is difficult to know in advance which therapy or combination of therapies is most appropriate. After assessing the patient at bedside, the clinician may decide that the patient requires a different therapy than planned, at which point he or she must return to a supply room to secure the proper therapy device or devices. This can be time consuming and can delay treatment at a time when prompt application of treatment is crucial. Second, in order to be prepared to deliver appropriate therapy, the healthcare provider must stock a number of devices, which presents the provider with the requirements of storage space and the need to deal with a number of suppliers. Furthermore, maintaining a number of different devices, and their attendant disposable accessories, to provide multiple therapy options increases costs to the healthcare provider and ultimately the patient. Third, in order to adequately utilize various devices a clinician must attend multiple training sessions, further increasing costs to the healthcare provider and patient.


Thus, there has been a need for a single apparatus which is capable of delivering a number of different breathing therapies, thereby eliminating the need for multiple devices, but which is also cost effective and does not significantly increase the time required to train operators in its use.


SUMMARY OF THE INVENTION

The present invention combines aerosol delivery, lung expansion therapy, and secretion clearance therapy into a single apparatus. In one aspect of the present invention, aerosol delivery can be combined with either pulsatile gas flow to provide a secretion clearance mode, or with a linear gas flow to provide a lung expansion mode. A third mode of operation is also disclosed in which linear gas flow without aerosol delivery is provided to the patient. The apparatus is comprised of a gas control box and a patient interface circuit. The gas control box controls the flow of gas from the gas source to the patient interface circuit. The patient interface circuit may be of single patient use and utilizes a fixed venturi and orifices open to the atmosphere for entrainment. The circuit also includes an exhalation opening which can be adjusted to maintain a positive pressure in the lungs at the end of exhalation (Positive End Expiratory Pressure or PEEP) without the stacking of successive volumes of gas in the airways (breath stacking). PEEP helps to open the airways and keep them open during the therapy. The apparatus is designed to minimize both clinical training requirements and operator errors during treatment. Additionally, with several therapies combined into one machine, the clinician can change therapies as needed without having to return to an equipment storage area to retrieve other devices. Storage requirements are reduced and the healthcare provider can deal with a single source vender for supplies, training, and repairs. It is expected that the healthcare provider would also achieve significant cost savings through the reduction in the number of different types of equipment required to perform the various treatments performed by the current apparatus.





BRIEF DESCRIPTION OF THE DRAWINGS

The invention will be better understood with reference to the drawings taken in connection with the detailed description which follows:



FIG. 1 is a view of the Patient Interface Circuit of the present invention;



FIG. 2 is an elevation view of the front face of the Gas Control Box of the present invention; and



FIG. 3 is a top-down view of the Gas Control Box of the present invention.





DETAILED DESCRIPTION

The present invention relates to a method and apparatus for treating a variety of breathing disorders experienced by patients. The invention is particularly suited to the treatment of atelectasis, the partial or total collapse of the lung, although those skilled in the art will appreciate that it has applications in treating other disorders as well. In a patient suffering from atelectasis, the lung can become partially or completely deflated due to fluid buildup, or from physical pressure such as from a trauma or tumor. If this occurs, the lung may not be able to re-inflate on its own, which can in turn exacerbate the patient's condition leading to a progressively worsening physical state or even death.


Treating a patient with atelectasis traditionally has required the use of multiple types of apparatus in order to provide the multiple types of treatment used. The present invention provides for a treatment apparatus that is enabled to provide multiple types of treatment, depending on the needs of the patient.


Referring to FIGS. 1, 2, and 3, the invention is comprised generally of a patient interface circuit 10, and a gas control box 50. Patient interface circuit 10 is fluidly connected to gas control box 50 and provides transportation of breathing treatment gas (not shown) from gas control box 50 to the patient (not shown). In a first embodiment, patient interface circuit 10 is comprised of a length of tubing 12 having first and second ends 28 and 30, a nebulizer 16, a manometer port 18, and handset 20, a selector ring 22 with a selector ring tab 24 and a mouthpiece 26. Tubing 12 is of medical grade quality of a type commonly available from medical supply houses. One or more connectors 14 may be used to enable first end 28 of tubing 12 to be removably connected to one or more circuit connectors 52 located on gas control box 50. However, the connectors 14 are not required in the event that tubing 12 is to be permanently connected to gas control box 50, or if gas control box 50 is fitted with a type of connector which is capable of interfacing with the ends of tubing 12 in such a way as to create a substantially gas tight connection between first end 28 of tubing 12 and gas control box 50. In a preferred embodiment, tubing 12 is double stranded, in that it is made up of two separate gas conduits that are longitudinally attached to each other, but which are not in fluid communication. Such tubing is commonly known as paratubing. If connectors 14 are used, one connector is required for each gas conduit, thus in the preferred embodiment, the connectors 14 and circuit connectors 52 may be color coded to assist the operator in making the correct connections between connectors 14 and circuit connectors 52 at gas control box 50.


Second end 30 of tubing 12 is fluidly connected to nebulizer 16 and provides gas flow which is used to entrain medicine or other substances contained within the nebulizer. Nebulizer technology is well known in the art and does not need to be recounted here. Examples of nebulizer technology may be seen at U.S. Pat. No. 6,929,003, Nebulizer Apparatus and Method, and U.S. Pat. No. 6,748,945, Nebulizer Apparatus and Method.


In an embodiment wherein tubing 12 is paratubing, the ends 30a and 30b of second end 30 may be separated and attached to nebulizer 16 at one or more entry points, or may bypass nebulizer 16 altogether. For example, first end 30a may enter nebulizer 16 at a point wherein the gas flowing from tubing 12 is used to aerosolize liquid medication held within nebulizer 16, while a second end may enter handset 20 at a point where it is directed through handset 20 so that it may entrain aerosolized medication so that it may be delivered to the patient. While the disclosed embodiment describes the invention as including nebulizer 16, it should be apparent to one skilled in the art that nebulizer 16 is not required for all applications and that the invention disclosed includes embodiments wherein nebulizer 16 is excluded.


In the preferred embodiment, gas exits nebulizer 16 and flows into handset 20, although, if nebulizer 16 is excluded, gas will flow directly from tubing 12 into handset 20. Once in handset 20, gas is entrained into an integral venturi, and then continues out mouthpiece 26 where it is inhaled by the patient. As the patient exhales back into mouthpiece 42 some of the exhalation gas exits an exhalation port (not shown). The exhalation port may be made larger or smaller by adjusting selection collar 22 using exhalation collar tab 24. In a preferred embodiment, proximal pressure is transmitted from patient back through pressure sensing tube 29, which is connected to manometer port 18. Pressure can be monitored by connecting a manometer (not shown) to manometer port 18.


Turning to FIGS. 2 and 3, FIG. 2 shows a front view perspective of gas control box 50, which may be enabled to regulate the flow of gas to the patient. Specifically, gas control box 50 may comprise one or more control devices of the type commonly known in the art such as valves, control interfaces, flow regulators, and the like. Patient interface circuit 20 is connected to gas control box 50 at one or more connectors 52. In a preferred embodiment, to begin a breathing therapy session, the clinician selects one of one or more breathing treatment modes depending on the condition of the patient. In the preferred embodiment shown, the clinician may select from between lung expansion CPEP™ mode (Continuous Positive Expiratory Pressure) or secretion mobilization CHFO™ mode (Continuous High-frequency Oscillation) although those skilled in the art will recognize that alternative therapies could be selected without deviating from the scope and content of the present invention. Mode selection is accomplished by moving mode selector switch 54 to the desired setting. The therapy is initiated by moving master switch 56 from the “off” position to the “on” position. After the therapy has been turned on the patient may begin the therapy by placing his or her mouth onto mouthpiece 26 and breathing normally.


If CPEP™ mode has been chosen, the gas flow is linear. The rate of flow can be adjusted by moving CPEP™ control knob 62. In the embodiment shown, counterclockwise rotation of control knob 62 results in increased flow, while clockwise rotation would decrease the gas flow. Other types of control mechanisms such as sliders, switches and digital interfaces could be substituted without deviating from the scope of the invention. Furthermore, the direction of movement of the control mechanism is not critical, and other variations would be within the scope of the invention.


IF CHFO™ mode has been chosen, gas flow is pulsatile in nature at substantially constant amplitude. In a preferred embodiment, gas flow is regulated or adjusted so that it is pulsitile at a rate of from 1 to 15 hertz at substantially constant amplitude.


Following the desired amount of time in therapy, master switch 56 is returned to the “off” position and patient interface circuit 20 may be disconnected.


In an alternative embodiment, gas control box 50 may be equipped with a nebulizer dryer spray nozzle. If a nebulizer 16 has been used in therapy, it may be desirable to reuse nebulizer 16 rather than simply discarding it. If nebulizer 16 is to be reused, however, it should be cleaned and dried prior to reuse. The clinician, or other operator, would thus wash nebulizer 16 in any of a number of known ways, including using soap and water. Following cleaning and/or rinsing, nebulizer 16 may be dried by moving nebulizer dryer switch 58 to the “on” position. This sends a flow of gas through dryer spray nozzle 60. Nebulizer 16 is held in front of spray nozzle 60 until it is dry. Neb dryer switch 58 is returned to the “off” position.



FIG. 3 shows a top view perspective of gas control box 50. Source gas connector 70 is connected to an appropriate gas source such as compressed air or oxygen.


Additional embodiments of the present invention are also possible. In another embodiment, a means for preventing inadvertent occlusion of the exhalation ports such as guards or screens positioned so as to prevent inadvertent blockage of the ports while still allowing gas flow through the ports.


In another embodiment, means for tracking patient use of the apparatus is included. Such means for tracking use would include any means whereby the identity of the individual using the apparatus may be tracked as well as the duration and type of treatment received. Such means could be as simple as printed records requiring patient acknowledgement that he or she received treatment, more complex means such as digital identification media capable of interfacing with the apparatus in such a way that the apparatus could identify the patient and then record treatment particulars itself.


In another embodiment, the described apparatus can be connected to, and be incorporated into, a ventilator circuit.


In another embodiment, the apparatus includes a means for supplying its own compressed gas rather than relying on an external gas source. Such means could include means for receiving and/or storing containers of compressed gas, or onboard compressor means for creating compressed gas.


In another embodiment, the disclosed apparatus includes means for measuring and/or displaying data concerning the treatment provided. Such means could include digital or analog gauges or displays and could be used to display pressure or flow rate at any point along patient interface circuit 10 or within gas control box 50. Means for measuring and displaying gas flow rate and pressure are well known in the art and will not be recounted herein.


In another embodiment, the apparatus includes means for displaying waveforms, such as a monitor.


In another embodiment, the apparatus includes means for transmitting and receiving data, either wirelessly or wired.


In another embodiment, the patient interface circuit is disposable.


In another embodiment, the apparatus includes means for collecting and analyzing data. As will be appreciated by those having skill in the art, many methods and devices may be used to collect and analyze data, such as sensors and computer systems.

Claims
  • 1. A breathing treatment apparatus comprising: a source of gas under pressure capable of providing substantially continuous positive gas flow;regulator means for regulating the flow of said substantially continuous positive gas flow between said source and a patient;selector means for selecting between one or more modes of operation, including at least a first mode of operation and a second mode of operation;means for interrupting said continuous positive gas flow;a patient interface circuit having one or more apertures open to the ambient to allow ingress and egress of flow and calibrated to allow patient exhalation and prevent stacking of successive volumes of gas in the airway of the patient, the patient interface circuit further having a removable nebulizer, a venturi tube fluidly connected to said one or more apertures, and a means for covering a portion of said one or more apertures to restrict ingress and egress of flow; anda gas control box housing the regulator means and the means for interrupting, the housing carrying the selector means, the housing having a first connector to which the source of gas couples, the housing having at least one second connector to which the patient interface circuit couples, and the housing having a nebulizer dryer nozzle through which gas is expelled to dry the nebulizer when the nebulizer is removed from the patient interface circuit.
  • 2. The apparatus of claim 1, further comprising an aerosol entrainment port fluidly connectable to said nebulizer for entrainment of aerosol.
  • 3. The apparatus of claim 1, wherein said means for interrupting said continuous positive gas flow is capable of interrupting said continuous positive gas flow at a rate of at least 1 hertz and at most 15 hertz whereby the gas flow becomes pulsatile with a substantially constant pressure amplitude.
  • 4. The apparatus of claim 1, wherein in at least one of said one or more modes of operation, the patient is provided with interrupted gas flow.
  • 5. The apparatus of claim 4, further comprising a nebulizer and an aerosol entrainment port fluidly connectable to said nebulizer for entrainment of aerosol.
  • 6. The apparatus of claim 5, wherein the patient is provided with interrupted gas flow and entrained aerosol.
  • 7. The apparatus of claim 1, wherein in at least one of said one or more modes of operation, the patient is provided with linear gas flow.
  • 8. The apparatus of claim 7, further comprising an aerosol entrainment port fluidly connectable to said nebulizer for entrainment of aerosol.
  • 9. The apparatus of claim 8 wherein the patient is provided with linear gas flow and entrained aerosol.
  • 10. The apparatus of claim 1, wherein the flow of said substantially continuous positive gas flow between said source and said patient is controlled by said regulator means.
  • 11. The apparatus of claim 1, wherein the means for interrupting said continuous positive gas flow is operator adjustable in order to achieve a desirable rate at which the flow of said continuous positive gas flow is interrupted.
  • 12. The apparatus of claim 1, further including a means to prevent inadvertent occlusion of said apertures.
  • 13. The apparatus of claim 1, further including a means for tracking use of said apparatus, whereby patient compliance with breathing therapy can be ascertained.
  • 14. The apparatus of claim 1, wherein said patient interface circuit is connected to and incorporated within a ventilator circuit.
  • 15. The apparatus of claim 1, wherein said gas under pressure comprises a container of compressed gas.
  • 16. The apparatus of claim 1, wherein said patient interface circuit includes a port connectable to a pressure manometer.
  • 17. The apparatus of claim 1, further including a means for measuring pressure.
  • 18. The apparatus of claim 1, further including a means for displaying pressure.
  • 19. The apparatus of claim 1, further including a means for displaying waveforms.
  • 20. The apparatus of claim 1, further including a means for collecting data.
  • 21. The apparatus of claim 1, further including a means analyzing data.
  • 22. The apparatus of claim 1, further including a communications port for at least one of transmitting and receiving data.
  • 23. The apparatus of claim 1, further including a nebulizer dryer switch coupled to the gas control box and movable to an “on” position to send a flow of gas through the nebulizer dryer nozzle.
  • 24. The apparatus of claim 1, wherein said patient interface circuit is for single patient use.
CROSS-REFERENCE TO RELATED APPLICATION

This application claims the benefit of priority from U.S. Provisional Application No. 60/746,355 filed on May 3, 2006.

US Referenced Citations (182)
Number Name Date Kind
402779 Steinhoff May 1889 A
1150238 Winbray Aug 1915 A
3083707 Seeler Apr 1963 A
3291122 Engstrom et al. Dec 1966 A
3301255 Thompson Jan 1967 A
3537448 Liston Nov 1970 A
3561444 Boucher Feb 1971 A
3584621 Bird et al. Jun 1971 A
3861386 Harris et al. Jan 1975 A
4054134 Kritzer Oct 1977 A
4062358 Kritzer Dec 1977 A
4182599 Eyrick et al. Jan 1980 A
4245633 Erceg Jan 1981 A
4436090 Darling Mar 1984 A
4558710 Eichler Dec 1985 A
4601465 Roy Jul 1986 A
4635857 Hughes Jan 1987 A
4770164 Lach et al. Sep 1988 A
4951659 Weiler et al. Aug 1990 A
4964404 Stone Oct 1990 A
4973047 Norell Nov 1990 A
4981295 Belman et al. Jan 1991 A
5018517 Liardet May 1991 A
5027809 Robinson Jul 1991 A
5067707 K{acute over (ø)}hnke Nov 1991 A
5069449 Wardwell Dec 1991 A
5107830 Younes Apr 1992 A
5127400 DeVries et al. Jul 1992 A
5150291 Cummings et al. Sep 1992 A
5193529 Labaere Mar 1993 A
5261394 Mulligan et al. Nov 1993 A
5277175 Riggs et al. Jan 1994 A
5322057 Raabe et al. Jun 1994 A
5355873 Del Bon et al. Oct 1994 A
5390665 Leach Feb 1995 A
5398676 Press et al. Mar 1995 A
5413110 Cummings et al. May 1995 A
5423313 Olsson et al. Jun 1995 A
5439430 Rubens et al. Aug 1995 A
5451190 Liardet Sep 1995 A
5535738 Estes et al. Jul 1996 A
5542416 Chalvignac Aug 1996 A
5547440 Rubens et al. Aug 1996 A
5570682 Johnson Nov 1996 A
5598839 Niles et al. Feb 1997 A
5617847 Howe Apr 1997 A
5664562 Bourdon Sep 1997 A
5666945 Davenport Sep 1997 A
5713349 Keaney Feb 1998 A
5823179 Grychowski et al. Oct 1998 A
5829429 Hughes Nov 1998 A
5906198 Flickinger May 1999 A
5937857 Caterini et al. Aug 1999 A
5938117 Ivri Aug 1999 A
5950619 Van Der Linden et al. Sep 1999 A
5964223 Baran Oct 1999 A
5970974 Van Der Linden et al. Oct 1999 A
6044841 Verdun et al. Apr 2000 A
6058932 Hughes May 2000 A
6076519 Johnson Jun 2000 A
6076520 Cooper Jun 2000 A
6079413 Baran Jun 2000 A
6085740 Ivri et al. Jul 2000 A
6085746 Fox Jul 2000 A
6116233 Denyer et al. Sep 2000 A
6152134 Webber et al. Nov 2000 A
6167881 Hughes Jan 2001 B1
6210345 Van Brunt Apr 2001 B1
6234167 Cox et al. May 2001 B1
6240919 MacDonald et al. Jun 2001 B1
6289892 Faithfull et al. Sep 2001 B1
6302105 Wickham et al. Oct 2001 B1
6336455 Howlett Jan 2002 B1
6340025 Van Brunt Jan 2002 B1
6355002 Faram et al. Mar 2002 B1
6363932 Forchione et al. Apr 2002 B1
6402046 Loser Jun 2002 B1
6405934 Hess et al. Jun 2002 B1
6412481 Bienvenu et al. Jul 2002 B1
6415791 Van Brunt Jul 2002 B1
6425393 Lurie et al. Jul 2002 B1
6427690 McCombs et al. Aug 2002 B1
6450163 Blacker et al. Sep 2002 B1
6467476 Ivri et al. Oct 2002 B1
6526976 Baran Mar 2003 B1
6540153 Ivri Apr 2003 B1
6540154 Ivri et al. Apr 2003 B1
6546927 Litherland et al. Apr 2003 B2
6550472 Litherland et al. Apr 2003 B2
6550476 Ryder Apr 2003 B1
6557549 Schmidt et al. May 2003 B2
6568387 Davenport et al. May 2003 B2
6571790 Weinstein Jun 2003 B1
6581596 Truitt et al. Jun 2003 B1
6581598 Foran et al. Jun 2003 B1
6581600 Bird Jun 2003 B2
6588421 Diehl et al. Jul 2003 B1
6588422 Berthon-Jones et al. Jul 2003 B1
6595203 Bird Jul 2003 B1
6598602 Sjoholm Jul 2003 B1
6598603 Andersson et al. Jul 2003 B1
6609517 Estes et al. Aug 2003 B1
6612303 Grychowski et al. Sep 2003 B1
6615831 Tuitt et al. Sep 2003 B1
6626175 Jafari et al. Sep 2003 B2
6631721 Salter et al. Oct 2003 B1
6640806 Yurko Nov 2003 B2
6644304 Grychowski et al. Nov 2003 B2
6644310 Delache et al. Nov 2003 B1
6644311 Truitt et al. Nov 2003 B1
6663574 Faram et al. Dec 2003 B2
6679258 Strom Jan 2004 B1
6694969 Heinonen et al. Feb 2004 B1
6702998 Conner Mar 2004 B2
6708688 Rubin et al. Mar 2004 B1
6718969 Rubin et al. Apr 2004 B1
6722362 Hete et al. Apr 2004 B2
6729334 Baran May 2004 B1
6737042 Rabinowitz et al. May 2004 B2
6752151 Hill Jun 2004 B2
6776159 Pelerossi et al. Aug 2004 B2
6805120 Jeffrey et al. Oct 2004 B1
6823866 Jafari et al. Nov 2004 B2
6848443 Schmidt et al. Feb 2005 B2
6851425 Jaffre et al. Feb 2005 B2
6854462 Berthon-Jones et al. Feb 2005 B2
6904906 Salter et al. Jun 2005 B2
6907881 Suki et al. Jun 2005 B2
6910479 Van Brunt Jun 2005 B1
6915803 Berthon-Jones et al. Jul 2005 B2
6932084 Estes et al. Aug 2005 B2
6948497 Zdrojkowski et al. Sep 2005 B2
6968840 Smith et al. Nov 2005 B2
7011091 Hill et al. Mar 2006 B2
7036500 Niles et al. May 2006 B2
7059324 Pelerossi et al. Jun 2006 B2
7066176 Jaffe et al. Jun 2006 B2
7070761 Rabinowitz et al. Jul 2006 B2
7100607 Zdrojkowski et al. Sep 2006 B2
7128069 Farrugia et al. Oct 2006 B2
7165547 Truitt et al. Jan 2007 B2
7188621 DeVries et al. Mar 2007 B2
7191776 Niles et al. Mar 2007 B2
7191780 Faram Mar 2007 B2
7204245 Johnson et al. Apr 2007 B2
7210480 Lurie et al. May 2007 B2
7232417 Plante Jun 2007 B2
7302949 Pelerossi et al. Dec 2007 B2
7445607 Plante Nov 2008 B2
7469700 Baran Dec 2008 B2
7472702 Beck et al. Jan 2009 B2
7472705 Baran Jan 2009 B2
7500481 Delache et al. Mar 2009 B2
7562657 Blanch et al. Jul 2009 B2
7600511 Power et al. Oct 2009 B2
7699054 Pelerossi et al. Apr 2010 B2
20010004893 Biondi et al. Jun 2001 A1
20020020412 Gilbert et al. Feb 2002 A1
20030051731 Be'eri et al. Mar 2003 A1
20030140925 Sapienza et al. Jul 2003 A1
20030205229 Crockford et al. Nov 2003 A1
20050061318 Faram Mar 2005 A1
20050109340 Tehrani May 2005 A1
20050165334 Lurie Jul 2005 A1
20050217666 Fink et al. Oct 2005 A1
20060084877 Ujhazy et al. Apr 2006 A1
20060144398 Doshi et al. Jul 2006 A1
20060178245 Schiller et al. Aug 2006 A1
20060201500 Von Hollen et al. Sep 2006 A1
20060243274 Lieberman et al. Nov 2006 A1
20060272642 Chalvignac Dec 2006 A1
20070017522 Be-Eri et al. Jan 2007 A1
20070017523 Be-Eri et al. Jan 2007 A1
20070089740 Baumert et al. Apr 2007 A1
20070186928 Be-Eri Aug 2007 A1
20080000475 Hill Jan 2008 A1
20080000477 Huster et al. Jan 2008 A1
20080015456 McCawley et al. Jan 2008 A1
20080091117 Choncholas et al. Apr 2008 A1
20080190429 Tatarek Aug 2008 A1
20080283060 Bassin Nov 2008 A1
20090020121 Bassin Jan 2009 A1
Related Publications (1)
Number Date Country
20070256690 A1 Nov 2007 US
Provisional Applications (1)
Number Date Country
60746355 May 2006 US